NanoBio, Merck enter research collaboration for RSV vaccine
Under the collaboration, the combination of Merck’s proprietary RSV antigen will be evaluated with NanoBio’s NanoStat adjuvant technology, for use as an intranasal vaccine. As per the deal,
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.